ANTHEM Share Price | Anthem Biosciences Ltd Stock Analysis & Recommendation

Q: Is Anthem Bioscienc overvalued or undervalued?

As of 29 August 2025, the valuation grade for Anthem Bioscienc has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 90.82, a Price to Book Value of 18.59, and an EV to EBITDA ratio of 65.82. These ratios are considerably higher than its peers, such as Sun Pharma with a PE of 33.34 and Divi's Lab at 70.28, both of which are categorized as expensive or very expensive.In comparison to other companies in the pharmaceuticals and biotechnology sector, Anthem Bioscienc's high valuation metrics suggest that investors are paying a premium for its stock. The PEG ratio is notably at 0.00, which raises concerns about growth expectations not being met. While the stock has shown a positive return of 4.51% over the past month compared to a decline in the Sensex, the overall valuation still points to an overvaluation scenario.

Q: How has been the historical performance of Anthem Bioscienc?

Answer:The historical performance of Anthem Bioscienc shows significant growth in various financial metrics from March 2024 to March 2025.Breakdown:Anthem Bioscienc reported net sales of 1,844.55 Cr in March 2025, an increase from 1,419.37 Cr in March 2024. The total operating income also rose to 1,844.55 Cr from 1,419.37 Cr, while total expenditure increased to 1,173.72 Cr from 914.40 Cr. This led to an operating profit (PBDIT) of 756.56 Cr, up from 568.67 Cr the previous year. Profit before tax reached 656.87 Cr, compared to 477.32 Cr in the prior year, resulting in a profit after tax of 451.26 Cr, which was higher than 367.31 Cr in March 2024. The earnings per share increased to 8.07 from 6.57, and the operating profit margin improved slightly to 36.37% from 35.58%. On the balance sheet, total assets grew to 2,789.64 Cr from 2,356.72 Cr, while total liabilities also increased to 2,789.64 Cr from 2,356.72 Cr. The cash flow from operating activities saw a notable rise to 418.00 Cr from 140.00 Cr, contributing to a net cash inflow of 132.00 Cr, reversing the outflow of 158.00 Cr in the previous year. Overall, Anthem Bioscienc demonstrated robust growth in sales, profits, and cash flow, indicating a strong financial performance.

Q: When is the next results date for Anthem Biosciences Ltd?

The next results date for Anthem Biosciences Ltd is scheduled for February 5, 2026.

Q: Should I buy, sell or hold Anthem Biosciences Ltd?

Based on the current situation of Anthem Biosciences Ltd, it would be advisable to hold your position in the company. The company demonstrates strong management efficiency, reflected in a high return on equity (ROE) of 19.93% and a low debt-to-equity ratio, indicating a solid financial foundation. Additionally, Anthem has shown impressive long-term growth, with net sales increasing at an annual rate of 29.80% and operating profit growing at 44.32%.However, recent results have raised some concerns. The company reported a significant decline in profit before tax (PBT) and profit after tax (PAT) compared to previous quarters, along with the lowest net sales figure recorded. This downturn suggests that the company is facing challenges that could impact its performance in the short term.Moreover, despite the strong growth in profits over the past year, the valuation appears expensive with a price-to-book ratio of 13, which may not be justified given the recent negative results.In summary, while the long-term growth prospects remain promising, the recent performance issues suggest that holding your investment for now would be prudent as you monitor how the company addresses these challenges.

Q: Why is Anthem Biosciences Ltd falling/rising?

As of 02-Apr, Anthem Biosciences Ltd's stock price is currently falling, with a change of -5.05, representing a decrease of 0.76%. The stock opened the day with a loss of 2.37% and reached an intraday low of Rs 648.05, which is a decline of 2.85%. This downward movement is further supported by a significant drop in investor participation, as the delivery volume on April 1st fell by 94.98% compared to the 5-day average. Despite the stock's performance being inline with the sector today, it is important to note that the stock has shown a negative trend over the past month, with a decline of 3.59%, while the benchmark Sensex has decreased by 8.62%. Additionally, while the stock is performing better than its moving averages over shorter periods (5, 20, 50, and 100 days), it remains below the 200-day moving average, indicating a longer-term weakness. Overall, the combination of a significant drop in trading volume, the stock's opening loss, and its position relative to moving averages contributes to the current decline in the stock price of Anthem Biosciences Ltd.

Mojo Score Change: Anthem Bioscienc has changed its score on 01 Apr 2026. Click here to unlock latest mojo score!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

3.59 lacs (-23.65%) Volume

Shareholding (Dec 2025)

FII

1.36%

Held by 48 FIIs

DII

0.27%

Held by 20 DIIs

Promoter

74.69%

Is Anthem Bioscienc overvalued or undervalued?

01-Sep-2025

As of August 29, 2025, Anthem Bioscienc is considered very expensive with a PE ratio of 90.82 and other high valuation metrics, indicating it is overvalued compared to peers, despite a recent positive return of 4.51%.

View full answer

How has been the historical performance of Anthem Bioscienc?

09-Nov-2025

Anthem Bioscienc experienced significant growth from March 2024 to March 2025, with net sales rising to 1,844.55 Cr and profit after tax increasing to 451.26 Cr. Key metrics such as operating profit and cash flow also improved, reflecting strong financial performance.

View full answer

When is the next results date for Anthem Biosciences Ltd?

28-Jan-2026

The next results date for Anthem Biosciences Ltd is February 5, 2026.

View full answer

Should I buy, sell or hold Anthem Biosciences Ltd?

02-Apr-2026

Why is Anthem Biosciences Ltd falling/rising?

03-Apr-2026

As of 02-Apr, Anthem Biosciences Ltd's stock is declining, with a 0.76% drop and significant reduction in trading volume. The stock has shown a negative trend over the past month and remains below its 200-day moving average, indicating longer-term weakness.

View full answer

Which are the latest news on Anthem Bioscienc?

04-Apr-2026

Anthem Biosciences Ltd Upgraded to Hold by MarketsMOJO Amid Mixed Financial Signals
Anthem Biosciences Ltd is Rated Sell

Which are the latest news on Anthem Bioscienc?

05-Apr-2026

Anthem Biosciences Ltd Upgraded to Hold by MarketsMOJO Amid Mixed Financial Signals
Anthem Biosciences Ltd is Rated Sell

Compare Anthem Bioscienc with Similar Stocks

Glaxosmi. Pharma Ajanta Pharma Ipca Labs

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Management Efficiency with a high ROE of 19.93%

Company has a low Debt to Equity ratio (avg) at 0 times

Healthy long term growth as Net Sales has grown by an annual rate of 29.80% and Operating profit at 44.32%

Negative results in Dec 25

With ROE of 17.7, it has a Very Expensive valuation with a 13 Price to Book Value

Majority shareholders : Promoters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 36,834 Cr (Mid Cap)

P/E

74.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.34

Return on Equity

17.74%

Price to Book

13.11

Revenue and Profits:

Net Sales:

423 Cr

(Quarterly Results - Dec 2025)

Net Profit:

93 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

0.96%

6 Months

-14.29%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Anthem Bioscienc for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Anthem Biosciences Ltd Upgraded to Hold by MarketsMOJO Amid Mixed Financial Signals

Anthem Biosciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 1 April 2026. This change reflects a nuanced reassessment of the company’s quality, valuation, financial trends, and technical outlook amid mixed quarterly results and evolving market conditions.

Read full news article

Anthem Biosciences Ltd is Rated Sell

Anthem Biosciences Ltd is rated Sell by MarketsMOJO. This rating was last updated on 09 Mar 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 01 April 2026, providing investors with the latest perspective on the company’s position.

Read full news article

Anthem Biosciences Ltd Surges 6.45% to Day's High of Rs 681 — Outperforms Sector by 5.5 Percentage Points

While the Sensex tumbled 2.26% on 27 Mar 2026, Anthem Biosciences Ltd defied the broader market weakness with a robust 6.45% gain, reaching an intraday high of Rs 681. This 5.5 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a market-wide lift.

Read full news article

Announcements

No announcement available

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

29.80%

EBIT Growth (5y)

44.32%

EBIT to Interest (avg)

56.77

Debt to EBITDA (avg)

0.16

Net Debt to Equity (avg)

-0.25

Sales to Capital Employed (avg)

0.62

Tax Ratio

28.85%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

8.96%

ROCE (avg)

32.59%

ROE (avg)

19.93%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

13.03

EV to EBIT

59.25

EV to EBITDA

52.55

EV to Capital Employed

19.31

EV to Sales

19.67

PEG Ratio

Dividend Yield

ROCE (Latest)

32.59%

ROE (Latest)

17.74%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

KST

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 22 Schemes (6.89%)

FIIs

Held by 48 FIIs (1.36%)

Promoter with highest holding

Ajay Bhardwaj (42.53%)

Highest Public shareholder

Viridity Tone Llp (3.8%)

Individual Investors Holdings

9.6%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -24.56% vs 2.64% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -43.50% vs 33.77% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "416.58",
          "val2": "552.23",
          "chgp": "-24.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "163.05",
          "val2": "225.66",
          "chgp": "-27.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.13",
          "val2": "2.23",
          "chgp": "-49.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-24.98",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "112.12",
          "val2": "198.43",
          "chgp": "-43.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "39.14%",
          "val2": "40.86%",
          "chgp": "-1.72%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,090.24",
          "val2": "863.40",
          "chgp": "26.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "421.08",
          "val2": "324.04",
          "chgp": "29.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.84",
          "val2": "5.20",
          "chgp": "-26.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "346.77",
          "val2": "255.63",
          "chgp": "35.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "38.62%",
          "val2": "37.53%",
          "chgp": "1.09%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,506.82",
          "val2": "1,361.66",
          "chgp": "10.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "584.13",
          "val2": "490.89",
          "chgp": "18.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.97",
          "val2": "6.99",
          "chgp": "-28.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-24.98",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "458.89",
          "val2": "383.62",
          "chgp": "19.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "38.77%",
          "val2": "36.05%",
          "chgp": "2.72%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,840.65",
          "val2": "1,417.54",
          "chgp": "29.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "689.01",
          "val2": "504.89",
          "chgp": "36.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "9.09",
          "val2": "9.14",
          "chgp": "-0.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "506.19",
          "val2": "374.78",
          "chgp": "35.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "37.43%",
          "val2": "35.62%",
          "chgp": "1.81%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

416.58

552.23

-24.56%

Operating Profit (PBDIT) excl Other Income

163.05

225.66

-27.75%

Interest

1.13

2.23

-49.33%

Exceptional Items

-24.98

0.00

Standalone Net Profit

112.12

198.43

-43.50%

Operating Profit Margin (Excl OI)

39.14%

40.86%

-1.72%

Values in Rs Cr.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is -24.56% vs 2.64% in Sep 2025

Standalone Net Profit

QoQ Growth in quarter ended Dec 2025 is -43.50% vs 33.77% in Sep 2025

All Quarterly Results

Half Yearly Results Snapshot (Standalone) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

1,090.24

863.40

26.27%

Operating Profit (PBDIT) excl Other Income

421.08

324.04

29.95%

Interest

3.84

5.20

-26.15%

Exceptional Items

0.00

Standalone Net Profit

346.77

255.63

35.65%

Operating Profit Margin (Excl OI)

38.62%

37.53%

1.09%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Half Yearly Results

Nine Monthly Results Snapshot (Standalone) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

1,506.82

1,361.66

10.66%

Operating Profit (PBDIT) excl Other Income

584.13

490.89

18.99%

Interest

4.97

6.99

-28.90%

Exceptional Items

-24.98

0.00

Standalone Net Profit

458.89

383.62

19.62%

Operating Profit Margin (Excl OI)

38.77%

36.05%

2.72%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Nine Monthly Results

Annual Results Snapshot (Standalone) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

1,840.65

1,417.54

29.85%

Operating Profit (PBDIT) excl Other Income

689.01

504.89

36.47%

Interest

9.09

9.14

-0.55%

Exceptional Items

0.00

Standalone Net Profit

506.19

374.78

35.06%

Operating Profit Margin (Excl OI)

37.43%

35.62%

1.81%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Annual Results

Company CV

About Anthem Biosciences Ltd

Anthem Biosciences Ltd

Mid Cap

Pharmaceuticals & Biotechnology

Anthem Biosciences Limited was originally incorporated as "Anthem Biosciences Private Limited", dated June 13, 2006, issued by RoC. Subsequently, Company was converted from a Private Company to a Public Company , followed by the change in name of the Company to "Anthem Biosciences Limited" and a Certificate of Incorporation upon the conversion was issued by RoC on December 10, 2024.

Company Coordinates

No Company Details Available